Pfizer Japan and Astellas have reached a co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment – Caduet Combination Tablets in Japan.
Pursuant to the agreement, Pfizer is responsible for manufacturing and sale of Caduet Combination tablets, and Pfizer and Astellas will co-promote it. Sales will be booked at Pfizer, and Astellas will receive fee in a way that the companies agreed. The term of this agreement ends July 2016.
Caduet Combination tablets is an oral combination drug of a hypertension treatment Norvasc tablets (amlodipine besylate) sold by Pfizer, and a hypercholesterolemia treatment Lipitor tablets (atorvastatin calcium) co-promoted by Pfizer and Astellas.
Caduet Combination tablets is a single tablet to combine the most prescribed drugs for hypertension and hypercholesterolemia to help with both treatments, and is expected to improve medication adherence. The tablets is approved in more than 70 countries/areas, and Pfizer had obtained approval to manufacture and market it in Japan on July 7, 2009.